Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1%

Zydus receives final approval from the USFDA for Clindamycin Phosphate Gel USP, 1% Ahmedabad, India, 20 September, 2023 Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and Drug Administration (USFDA) for Clindamycin Phosphate Gel USP, 1% (USRLD: Cleocin T Gel, 1%). Clindamycin Phosphate Gel USP, 1% is used to treat acne. It helps to decrease the number of acne lesions. Clindamycin is an antibiotic which works by stopping the growth of bacteria. The drug will be manufactured at the group’s topical manufacturing facility at Changodar, Ahmedabad (India). Clindamycin Phosphate Gel USP, 1% had annual sales of USD 37 mn in the United States (IQVIA MAT July 2023). The group now has 381 approvals and has so far filed over 44 4* ANDAs since the commencement of the filing process in FY 2003-04. (*as of 30th June 2023) ***

The release as fetched from its publisher. zyduslife.com ↗